Cyclacel Pharmaceuticals, Inc. News Releases https://investor.cyclacel.com/ Cyclacel Pharmaceuticals, Inc. News Releases en Cyclacel Pharmaceuticals Reports First Quarter 2019 Financial Results https://investor.cyclacel.com/news-releases/news-release-details/cyclacel-pharmaceuticals-reports-first-quarter-2019-financial Conference Call Scheduled May 14, 2019 at 4:30 p.m. ET BERKELEY HEIGHTS, N.J. , May 14, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today Tue, 14 May 2019 16:05:00 -0400 Cyclacel Pharmaceuticals, Inc. News Releases 15676 Cyclacel Pharmaceuticals to Release First Quarter 2019 Financial Results https://investor.cyclacel.com/news-releases/news-release-details/cyclacel-pharmaceuticals-release-first-quarter-2019-financial BERKELEY HEIGHTS, N.J. , May 08, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce first quarter 2019 financial results on Wed, 08 May 2019 07:00:00 -0400 Cyclacel Pharmaceuticals, Inc. News Releases 15666 Cyclacel Announces Presentation of Phase 1 Data of Sapacitabine Regimen in Patients With BRCA Mutant Breast Cancer at AACR 2019 https://investor.cyclacel.com/news-releases/news-release-details/cyclacel-announces-presentation-phase-1-data-sapacitabine -- Clinical benefit in PARP inhibitor-naïve patients supports ongoing Phase 1b/2 IST study of sapacitabine and olaparib combination in BRCA mutant breast cancer -- BERKELEY HEIGHTS, N.J. , April 01, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. Mon, 01 Apr 2019 07:00:00 -0400 Cyclacel Pharmaceuticals, Inc. News Releases 15646 Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results https://investor.cyclacel.com/news-releases/news-release-details/cyclacel-pharmaceuticals-reports-fourth-quarter-and-full-year-8 – Conference Call Scheduled March 27, 2019 at 4:30 p.m. EDT – BERKELEY HEIGHTS, N.J. , March 27, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company") a biopharmaceutical company developing innovative medicines based on cancer cell Wed, 27 Mar 2019 16:05:00 -0400 Cyclacel Pharmaceuticals, Inc. News Releases 15631 Publication Identifies Cyclin E as Key Resistance Pathway to Breast Cancer Treated by CDK4/6 Inhibitors and Thereby Amenable to Treatment by CYC065 CDK2/9 Inhibitor https://investor.cyclacel.com/news-releases/news-release-details/publication-identifies-cyclin-e-key-resistance-pathway-breast -- PALOMA-3 study gene expression profiling shows that CDK2 is a key kinase bypass mechanism after treatment with palbociclib plus hormone therapy -- -- Cyclin E is proposed as the first predictive biomarker of palbociclib efficacy -- BERKELEY HEIGHTS, N.J. Mon, 25 Mar 2019 07:00:00 -0400 Cyclacel Pharmaceuticals, Inc. News Releases 15621 Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2018 Financial Results https://investor.cyclacel.com/news-releases/news-release-details/cyclacel-pharmaceuticals-release-fourth-quarter-and-full-year-4 BERKELEY HEIGHTS, N.J. , March 20, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fourth quarter and full year 2018 financial Wed, 20 Mar 2019 07:00:00 -0400 Cyclacel Pharmaceuticals, Inc. News Releases 15616 Cyclacel to Participate in 31st Annual ROTH Conference March 18-19 https://investor.cyclacel.com/news-releases/news-release-details/cyclacel-participate-31st-annual-roth-conference-march-18-19 BERKELEY HEIGHTS, N.J. , March 13, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced that it will participate in the 31 st Annual ROTH Wed, 13 Mar 2019 07:00:00 -0400 Cyclacel Pharmaceuticals, Inc. News Releases 15611 Cyclacel Announces Abstracts Selected for Presentation at the American Association for Cancer Research Annual Meeting 2019 https://investor.cyclacel.com/news-releases/news-release-details/cyclacel-announces-abstracts-selected-presentation-american-0 BERKELEY HEIGHTS, N.J. , March 05, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced that an abstract highlighting clinical data for Tue, 05 Mar 2019 07:00:00 -0500 Cyclacel Pharmaceuticals, Inc. News Releases 15601 Cyclacel Pharmaceuticals to Present at the 2019 BIO CEO & Investor Conference https://investor.cyclacel.com/news-releases/news-release-details/cyclacel-pharmaceuticals-present-2019-bio-ceo-investor BERKELEY HEIGHTS, N.J. , Feb. 05, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will present at the 2019 Tue, 05 Feb 2019 07:00:00 -0500 Cyclacel Pharmaceuticals, Inc. News Releases 15581 Cyclacel Pharmaceuticals Reviews 2018 Achievements and Announces Key Business Objectives for 2019 https://investor.cyclacel.com/news-releases/news-release-details/cyclacel-pharmaceuticals-reviews-2018-achievements-and-announces BERKELEY HEIGHTS, N.J. , Jan. 07, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today provided a business update reviewing 2018 Mon, 07 Jan 2019 07:00:00 -0500 Cyclacel Pharmaceuticals, Inc. News Releases 15551